1. Home
  2. DAKT vs BBIO Comparison

DAKT vs BBIO Comparison

Compare DAKT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daktronics Inc.

DAKT

Daktronics Inc.

HOLD

Current Price

$18.90

Market Cap

872.1M

Sector

Industrials

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$74.97

Market Cap

14.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAKT
BBIO
Founded
1968
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.1M
14.4B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
DAKT
BBIO
Price
$18.90
$74.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
20
Target Price
$26.00
$75.75
AVG Volume (30 Days)
395.9K
2.0M
Earning Date
12-10-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$770,283,000.00
$353,780,000.00
Revenue This Year
$12.94
$128.44
Revenue Next Year
$7.16
$76.14
P/E Ratio
$128.40
N/A
Revenue Growth
N/A
62.46
52 Week Low
$10.24
$25.34
52 Week High
$24.38
$75.24

Technical Indicators

Market Signals
Indicator
DAKT
BBIO
Relative Strength Index (RSI) 50.83 68.19
Support Level $17.09 $70.35
Resistance Level $21.28 $75.10
Average True Range (ATR) 0.87 2.33
MACD 0.23 -0.13
Stochastic Oscillator 44.13 98.77

Price Performance

Historical Comparison
DAKT
BBIO

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: